Northern Trust
KPTI icon

Northern Trust’s Karyopharm Therapeutics KPTI Stock Holding History

Northern Trust’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$215K Buy
38,556
+9,533
+33% +$72.7K ﹤0.01% 3928
2025
Q4 		$214K Buy
29,023
+10,147
+54% +$62.1K ﹤0.01% 3962
2025
Q3 		$123K Sell
18,876
-34
-0.2% -$183 ﹤0.01% 4085
2025
Q2 		$81.5K Hold
18,910
– – ﹤0.01% 4151
2025
Q1 		$70.7K Sell
18,910
-5
-0% -$43 ﹤0.01% 4172
2024
Q4 		$192K Buy
18,915
+3,604
+24% +$43.6K ﹤0.01% 4005
2024
Q3 		$191K Sell
15,311
-42,700
-74% -$531K ﹤0.01% 3904
2024
Q2 		$755K Sell
58,011
-5,909
-9% -$97.8K ﹤0.01% 3357
2024
Q1 		$1.45M Sell
63,920
-2,490
-4% -$43.7K ﹤0.01% 3138
2023
Q4 		$862K Buy
66,410
+695
+1% +$9.37K ﹤0.01% 3365
2023
Q3 		$1.32M Sell
65,715
-5,558
-8% -$125K ﹤0.01% 3166
2023
Q2 		$1.91M Buy
71,273
+16,290
+30% +$702K ﹤0.01% 3034
2023
Q1 		$3.21M Buy
54,983
+5,267
+11% +$260K ﹤0.01% 2718
2022
Q4 		$2.54M Sell
49,716
-536
-1% -$37.2K ﹤0.01% 2872
2022
Q3 		$4.12M Sell
50,252
-955
-2% -$71.3K ﹤0.01% 2615
2022
Q2 		$3.46M Buy
51,207
+251
+0.5% +$23K ﹤0.01% 2741
2022
Q1 		$5.63M Sell
50,956
-747
-1% -$93.1K ﹤0.01% 2511
2021
Q4 		$4.99M Buy
51,703
+566
+1% +$56.4K ﹤0.01% 2684
2021
Q3 		$4.46M Sell
51,137
-1,215
-2% -$126K ﹤0.01% 2795
2021
Q2 		$8.11M Buy
52,352
+2,683
+5% +$389K ﹤0.01% 2521
2021
Q1 		$7.84M Sell
49,669
-2,388
-5% -$503K ﹤0.01% 2460
2020
Q4 		$12.1M Sell
52,057
-4,725
-8% -$1.09M ﹤0.01% 2133
2020
Q3 		$12.4M Sell
56,782
-3,391
-6% -$829K ﹤0.01% 1963
2020
Q2 		$17.1M Buy
60,173
+9,151
+18% +$2.71M ﹤0.01% 1752
2020
Q1 		$14.7M Buy
51,022
+1,841
+4% +$508K ﹤0.01% 1616
2019
Q4 		$14.1M Sell
49,181
-278
-0.6% -$60.3K ﹤0.01% 1955
2019
Q3 		$7.14M Buy
49,459
+8,475
+21% +$1.15M ﹤0.01% 2354
2019
Q2 		$3.68M Buy
40,984
+801
+2% +$64.3K ﹤0.01% 2724
2019
Q1 		$3.52M Sell
40,183
-376
-0.9% -$41.7K ﹤0.01% 2758
2018
Q4 		$5.7M Sell
40,559
-889
-2% -$150K ﹤0.01% 2421
2018
Q3 		$10.6M Buy
41,448
+1,316
+3% +$364K ﹤0.01% 2222
2018
Q2 		$10.2M Buy
40,132
+13,646
+52% +$3.38M ﹤0.01% 2254
2018
Q1 		$5.33M Buy
26,486
+772
+3% +$154K ﹤0.01% 2539
2017
Q4 		$3.7M Sell
25,714
-2,035
-7% -$327K ﹤0.01% 2786
2017
Q3 		$4.57M Buy
27,749
+724
+3% +$104K ﹤0.01% 2685
2017
Q2 		$3.67M Buy
27,025
+7,225
+36% +$1.07M ﹤0.01% 2811
2017
Q1 		$3.81M Buy
19,800
+440
+2% +$70.6K ﹤0.01% 2717
2016
Q4 		$2.73M Buy
19,360
+1,206
+7% +$163K ﹤0.01% 2917
2016
Q3 		$2.65M Buy
18,154
+989
+6% +$119K ﹤0.01% 2922
2016
Q2 		$1.73M Buy
17,165
+622
+4% +$80.8K ﹤0.01% 3123
2016
Q1 		$2.21M Sell
16,543
-101
-0.6% -$11.1K ﹤0.01% 2923
2015
Q4 		$3.31M Buy
16,644
+560
+3% +$121K ﹤0.01% 2732
2015
Q3 		$2.54M Buy
16,084
+4,489
+39% +$1.2M ﹤0.01% 2896
2015
Q2 		$4.73M Buy
11,595
+191
+2% +$82.6K ﹤0.01% 2555
2015
Q1 		$5.24M Buy
11,404
+1,499
+15% +$646K ﹤0.01% 2474
2014
Q4 		$5.56M Sell
9,905
-178
-2% -$101K ﹤0.01% 2440
2014
Q3 		$5.28M Buy
10,083
+4,119
+69% +$2.32M ﹤0.01% 2463
2014
Q2 		$4.16M Sell
5,964
-434
-7% -$202K ﹤0.01% 2643
2014
Q1 		$2.96M Sell
6,398
-666
-9% -$338K ﹤0.01% 2895
2013
Q4 		$2.43M Buy
+7,064
New +$1.95M ﹤0.01% 3035

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Northern Trust's KPTI Position: Q1 2026 in Review

Northern Trust increased its Karyopharm Therapeutics (KPTI) stake by 33% in Q1 2026, buying an estimated $72.7K and bringing the position to 38,556 shares worth $215K. The position accounts for ﹤0.01% of the portfolio, ranked #3928.

Northern Trust first reported a position in KPTI in Q4 2013 and has held it in 50 quarters since. The position peaked at $17.1M in Q2 2020. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Northern Trust held 38,556 shares of Karyopharm Therapeutics worth $215K as of Q1 2026.
  • Northern Trust bought 9,533 Karyopharm Therapeutics shares in Q1 2026, an estimated $72.7K.
  • Karyopharm Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #3928 holding.
  • Northern Trust first reported a position in Karyopharm Therapeutics in Q4 2013 and has held it in 50 quarters since.
  • Northern Trust's Karyopharm Therapeutics position peaked at $17.1M in Q2 2020.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.